Gliomatosis cerebri(GC) is a highly aggressive, rare form of neuroepithelial tumor. Due to the diffuse nature of the tumor, its pathological grade is not conclusively established unless a biopsy is carried out from multiple sites. The tumor typically infiltrates the cortex in the subpial plane and also insinuates in the perineuronal space and around the Virchow-Robin spaces with relative preservation of the underlying brain parenchyma. Most of the previously reported cases of GC are astrocytic in nature. In this study, we report 2 pediatric patients of GC with oligodendroglial morphology on histopathological examination. In view of the rarity of the oligodendroglial phenotype of gliomatosis cerebri as well as the rare occurrence in children, we report these 2 cases.

1.
Nevin S: Gliomatosis Cerebri. Brain 1938;61:170–191.
2.
Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumors. Brain Pathol 1993;3:255–268.
3.
Balko MG, Blisard KS, Samaha FJ: Oligodendroglial gliomatosis cerebri. Hum Pathol 1992;23:706–707.
4.
Gutowski NJ, Gomez-Anson B, Torpey N, Tevesz T, Miller DH, Rudge P: Oligodendroglial gliomatosis cerebri: 1H-MRS suggests elevated glycine/inositol levels. Neuroradiology 1999;41:650–653.
5.
Jennings MT, Frenchman M, Shehab T, et al: Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 1995;10:35–45.
6.
Keene DL, Jimenez C, Hsu E: MRI diagnosis of gliomatosis cerebri. Pediatr Neurol 1999;20:148–151.
7.
Kayemba-Kay’s S, Duchene S, Foo Cheung L, Loiseau-Corvez MN: Gliomatosis cerebri: report of two pediatric cases. Int Pediatr 2004;19:220–223.
8.
Caroli E, Orlando ER, Ferrante L: Gliomatosis cerebri in children: case report and clinical considerations. Childs Nerv Syst 2005;21:1000–1003.
9.
Lantos PL, Bruner JM: Gliomatosis cerebri; in Kleihues P, Cavenee WK (eds): World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the Nervous System. Lyon, IARC Press, 2000, pp 92–93.
10.
Schenker IM, Evans JP: Diffuse cerebral gliomatosis. J Neuropathol Exp Neurol 1943;2:178–189.
11.
Willis RA: Pathology of Tumors, ed 4. London, Butterworth, 1967, p 811.
12.
Russell DS, Rubinstein LJ: Tumors of central neuroepithelial origin; in Pathology of Tumors of the Nervous System. Baltimore, Williams & Wilkins, 1989. pp 146–148.
13.
Malamud N, Wise BL, Jones OW: Gliomatosis cerebri. J Neurosurg 1952;9:409–417.
14.
Wilson NW, Symon L, Lantos PL: Gliomatosis cerebri: report of a case presenting as a focal cerebral mass. J Neurol 1987;234:445–447.
15.
Kleihues P, Cavenee WK (eds): World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the Central Nervous System. Lyon, IARC Press, 2000.
16.
Hecht BK, Turc C, Chatel M, Lonjon M, Roche JL, Gioanni J, Hecht F, Gaudray P: Chromosomes in gliomatosis cerebri. Genes Chromosomes Cancer 1995;14:149–153.
17.
Ross IB, Robitaille Y, Villemure JG, Tampieri D: Diagnosis and management of gliomatosis cerebri: recent trends. Surg Neurol 1991;36:431–440.
18.
Louis E, Keime-Guibert F, Delattre JY, Sanson M: Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri. Neurology 2003;60:151.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.